يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Naozumi Harada"', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 1
    First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

    المؤلفون: Naozumi Harada, Katsunori Uchida, Takeshi Sasaki, Yoshiki Sugimura, Yasutaka Tono, Gill A Webster, Naoyuki Katayama, Shinichi Kageyama, Hiroshi Shiku, Toshiro Mizuno, Yoshihiro Miyahara, Hideki Kanda, Mikiya Ishihara, Eiichi Sato, Taizo Shiraishi, Yasuhide Hori, Norihito Soga, Hiroaki Ikeda, Daisuke Muraoka

    المصدر: Cancer Immunology, Immunotherapy

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Antibodies, Neoplasm, medicine.medical_treatment, Nod2 Signaling Adaptor Protein, CD8-Positive T-Lymphocytes, TLR9, 0302 clinical medicine, Neoplasms, Cancer vaccine, Immunology and Allergy, Aged, 80 and over, Mice, Inbred BALB C, Vaccination, Middle Aged, NY-ESO-1 antigen, Tolerability, 030220 oncology & carcinogenesis, Female, NY-ESO-1, Adjuvant, Adult, medicine.medical_specialty, Combination therapy, Immunology, Cancer Vaccines, NOD2, 03 medical and health sciences, Interferon-gamma, Antigen, Antigens, Neoplasm, Internal medicine, Cell Line, Tumor, medicine, Animals, Humans, Aged, business.industry, Cancer, Membrane Proteins, medicine.disease, 030104 developmental biology, Clinical Trial Report, Toll-Like Receptor 9, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3477f6e7567b8e1a8173e128b6e3de91Test
    http://europepmc.org/articles/PMC7113205Test


    أضف إلى المفضلة
  2. 2
    NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma

    المؤلفون: Naozumi Harada, Yasuhiro Nagata, Yoshihiro Miyahara, Shinichi Kageyama, Hiroshi Shiku, Eiichi Sato, Hiroaki Ikeda, Shugo Ueda, Taizo Shiraishi

    المصدر: Oncotarget

    مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Gastroenterology, immune response, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antigen, Internal medicine, Medicine, NY-ESO-1, esophageal cancer, Adverse effect, MAGE-A4, biology, business.industry, Cancer, Esophageal cancer, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Cancer vaccine, Antibody, business, cancer vaccine, Research Paper

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4a87fe043e86d3493aedad2a44eb05Test
    https://pubmed.ncbi.nlm.nih.gov/30542513Test


    أضف إلى المفضلة
  3. 3
    Outcomes of pregnancy during interferon beta-1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study

    المؤلفون: Takahiko Saida, Haruki Makioka, Yuko Shimizu, Naozumi Harada, Jun Ichi Kira, Shoko Nakabayashi

    المصدر: Clinical and Experimental Neuroimmunology. 6:402-408

    مصطلحات موضوعية: Gynecology, medicine.medical_specialty, Pregnancy, Pediatrics, business.industry, Multiple sclerosis, Immunology, Neuroscience (miscellaneous), Interferon beta-1a, Postmarketing surveillance, Abortion, medicine.disease, Immunology and Microbiology (miscellaneous), Interim, medicine, Childbirth, Neurology (clinical), Adverse effect, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ed7df70bde6b9e0da0c525c084b9dad9Test
    https://doi.org/10.1111/cen3.12231Test


    أضف إلى المفضلة
  4. 4
    PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER

    المؤلفون: Takeshi Sasaki, Yoshiki Sugimura, Hiroshi Shiku, Naozumi Harada, Mikiya Ishihara, Norihito Soga, Yoshihiro Miyahara, Shinichi Kageyama, Yasuhide Hori, Hideki Kanda

    المصدر: Journal of Urology. 195

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Combination therapy, business.industry, Urology, Cancer, Castration resistant, medicine.disease, Clinical study, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Refractory, Internal medicine, medicine, Cancer vaccine, NY-ESO-1, business, 030215 immunology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::d8516b28da67f39a26659cfceb91599cTest
    https://doi.org/10.1016/j.juro.2016.02.681Test


    أضف إلى المفضلة
  5. 5
    Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis

    المؤلفون: Toshiyuki Hirakata, Takahiko Saida, Naozumi Harada, Jun Ichi Kira, Yasuhiro Ueno

    المصدر: Multiple sclerosis and related disorders. 7

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, MedDRA, Kaplan-Meier Estimate, Injections, Intramuscular, 03 medical and health sciences, Disability Evaluation, Young Adult, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, Adjuvants, Immunologic, Japan, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Dosing, Adverse effect, Expanded Disability Status Scale, business.industry, Multiple sclerosis, Interferon beta-1a, General Medicine, Middle Aged, medicine.disease, Surgery, Treatment Outcome, Neurology, Tolerability, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04827809f961c2854890d7ec3aef7c2bTest
    https://pubmed.ncbi.nlm.nih.gov/27237769Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث